Systagenix has been awarded with a prestigious Gatwick Diamond Business Award for its pioneering WoundChek Protease Status device.
The company was presented with the award for innovation and technology after demonstrating the way in which its first-of-a-kind product is enhancing business performance.
Launched earlier this year, WoundChek is a unique point-of-care diagnostic test for wounds that allows elevated protease activity to be rapidly identified, which in turn makes it easier to diagnose chronic problems.
Having been granted CE Mark accreditation, the device achieved its first sale in February 2012 after being purchased by Brentwood Community Hospital.
Victory at the Gatwick Diamond Business Awards saw Systagenix successfully compete with more than 450 international firms, underlining the revolutionary nature of the product launch.
Ernest Waaser, chief executive officer of Systagenix, said: "Bringing Woundchek Protease Status to the market is a huge achievement for Systagenix and a long-awaited innovation milestone in the woundcare field."